Please ensure Javascript is enabled for purposes of website accessibility

Should Investors Be Worried About Merck's Keytruda?

By Mark Prvulovic - Jan 23, 2020 at 9:17AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There have been some worrying developments for the cancer superdrug, but are they worth losing sleep over?

Merck's (MRK 2.11%) cancer immunology drug, Keytruda, is already one of the best-selling drugs in the world and is well on track to becoming the No. 1 drug by revenue within the next few years. Having already been approved to treat a number of different cancer types, Keytruda is poised to play a crucial role in the company's future sales growth.

Over the past couple of weeks, however, Keytruda has been hit by some mixed, if not outright disappointing, clinical results. Let's take a closer look at some of these developments and whether they should worry pharmaceutical investors.

Capsules, pills, a glass medication bottle, and pills in blister packs lying on a surface.

Image source: Getty Images.

The lung cancer trial setback

The most notable setback so far in 2020 for the drug involved a phase 3 trial treating small-cell lung cancer (SCLC). Merck announced on Jan. 7 that Keytruda failed to extend the lifespan of patients who are diagnosed with the condition, although it helped slow down cancer progression in combination with chemotherapy.

It's worth noting that other major cancer drugs that work similarly to Keytruda have also failed to see positive results in the SCLC patient population. Bristol-Myers Squibb's Opdivo failed to show strong results in a late-stage clinical trial, later failing another trial in treating non-small-cell lung cancer. Small-cell and non-small-cell are the two main types of lung cancer, with small-cell cancer cells appearing small and round under a microscope while non-small-cell cancer cells appear larger. The small-cell cancer cells spread more aggressively than their non-small-cell counterparts, and patients diagnosed with SCLC have fewer treatment options open to them than patients diagnosed with non-small-cell lung cancer (NSCLC).

Keytruda and Opdivo are both PD-1 inhibitors, a type of drug that suppresses PD-1 (programmed cell death 1) proteins in the body, which is responsible for signaling to the immune system to avoid specific cells. The idea is that the body's immune system will turn back on and aggressively target the cells that don't have this protein -- in this instance, cancer cells.

However, drugs that operate in a different manner have had a measure of success in treating SCLC. They include AstraZeneca's Imfiniz and Roche's Tecentriq, both of which target the slightly different PD-L1 pathway. Tecentriq, in particular, has been approved as a first-line treatment for patients with SCLC.

Is this a big deal?

Investors should remember that SCLC accounts for only 10% to 15% of all lung cancer cases, with the vast majority being a type of non-small-cell lung cancer. For this latter category, Keytruda has already received approval from the Food and Drug Administration (FDA) as a treatment, albeit for patients who aren't suitable for surgery or chemoradiation. Even if Keytruda ends up failing to capture the smaller SCLC market and cedes it to other drugmakers, the NSCLC population -- which is represents 85% to 90% of all lung cancer patients -- is a massive market in and off itself. Current estimates predict that the global NSCLC market size will reach $43.7 billion by 2026 

However, Keytruda isn't strictly a lung cancer drug; it's approved to treat a variety of other cancers like lymphoma, melanoma, gastric, cervical, and head and neck cancer, whether by itself or in combination with other drugs. When you add all these potential markets together, a setback in the relatively narrow small-cell lung cancer indication becomes even less worrisome.

It's also worth mentioning that Keytruda has a plethora of ongoing studies, and of course not every study is going to yield positive results. A simple search on the internet will reveal a number of clinical flops, most notable of which are a late-stage breast cancer trial that fell apart in May 2019. Another notable failure came from two phase 3 trials concerning Keytruda's effectiveness in treating multiple melanoma, a type of cancer that affects a specific type of white blood cell -- the plasma cells -- found primarily in the bone marrow. 

It's to be expected that Keytruda won't hit a clinical home run every time a study comes out. In the big picture, however, things look pretty solid.

What about the potential competition?

Looking at the domestic U.S. market, which accounts for the majority of Keytruda's revenue, Merck faces perhaps the most competition from Roche's Tecentriq. Despite bringing in only one-tenth the gross revenue of Keytruda in 2018, it is seen as the top front-runner behind Merck's cancer drug, holding an edge in clinical results in treating SCLC. While not a short-term threat, Tecentriq poses an increasing "long-term risk" to Keytruda's position, according to Wall Street analysts.

In international markets, such as China, local competitors are popping up that can siphon away market share. Just recently, BeiGene announced strong results for its non-small-cell lung cancer drug, tislelizumab, which, if it receives regulatory approval, would directly compete with Keytruda in China.

Both in the U.S. and internationally, however, it's unlikely that Keytruda's dominance will be shaken up too much in the next year or two. However, within five to 10 years, it's definitely possible that rival drugs could catch up with, or even overtake, Keytruda in terms of market share. Keytruda is also protected from generic competition for several more years, with its patent protection expiring in 2028. 

Future Keytruda catalysts to watch for

Keytruda is predicted to reach over $10 billion in annual revenue for 2019, and is well on track to reach peak annual sales of $22.5 billion by 2025. Neither competition nor the occasional clinical setback is likely to do much to change this.

However, there still are some major catalysts for the cancer drug that investors might want to keep an eye on. Most notably, results from a phase 3 trial in the realm of breast cancer is expected to come out in the first quarter while another phase 3 trial for renal cell cancer expected around April. 

As for Merck's stock, it trades at a reasonable 25.2 price-to-earnings (P/E) ratio, much lower than AstraZeneca's 63.1 P/E but a bit pricier than Bristol-Myers' 19.4. In some ways, it's surprising that Merck doesn't trade at a higher premium considering Keytruda's revenue projections, but I wouldn't say the stock is underpriced. Overall, I'd say Merck looks like a pretty good buy at the moment, with Keytruda's financial and clinical positions remaining unthreatened for at least the next couple of years.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$92.32 (2.11%) $1.91
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$40.12 (0.93%) $0.37
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$64.49 (2.14%) $1.35
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$76.91 (1.46%) $1.11
BeiGene Stock Quote
BeiGene
BGNE
$129.18 (-2.78%) $-3.69

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.